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Abstract 
The interaction of reactive derivatives of oligonucleotides bearing a 4-[(N-2-chloroethyl-N-methyl)amino]benzylamin res due at the 5’-terminal 
phosphate with serum blood proteins has been investigated. It was found that the compounds react with serum albumin and immunoglobulins M 
and G, the reactivity increasing in the order: albumin < IgG < IgM. The reactions with immunoglobulins were inhibited in the presence of different 
oligonucleotides, DNA and heparin, suggesting the oligonucleotide binding to some cationic region of the proteins. Myoglobin inhibited the 
interaction of oligonucleotide derivatives with myoglobin-specific monoclonal antibodies which indicates that the derivatives interact with the proteins 
within or near the antigen binding site. 
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1. Introduction 
The ability of oligonucleotide derivatives targeted to 
specific genetic messages to suppress the multiplication 
of viruses in cell cultures and to affect expression of 
specific genes (for reviews see [l]) suggests that com- 
pounds of this type may become efficient therapeutics. 
A few animal tests have already demonstrated antiviral 
activity of oligonucleotides at the organism level and 
recently human tests have been started [2]. However the 
fate of the compounds in the organism is poorly investi- 
gated and little is known about heir interactions with 
biomolecules in the organism. Oligonucleotides imitate 
natural nucleic acids and may be expected to interact not 
only with the target nucleic acids but also with a number 
of proteins of nucleic acids metabolism, polymerases of 
nucleic acids, ribosomes and perhaps with many other 
known and unknown factors capable of binding to nu- 
cleic acids. These interactions may influence distribution 
and the fate of oligonucleotides in the organism. 
Earlier we have investigated the distribution of ol- 
igonucleotide derivatives in mice. It was found that they 
* Corresponding author. 
Abbreviations: PT,~ oligodeoxyribothymidilate 16-mer; dsDNA, dou- 
ble-stranded DNA; CIRCH,NH-, 4-[(N-2-chloroethyl-N-methyl)- 
aminolbenzylamine r sidue. 
enter all organs showing less efficient accumulation in 
the brain and persist in the blood in an undegraded state 
for 20-60 min. [3]. Also it was found that the life time 
of oligonucleotides in the organism can be prolonged by 
chemical modification of terminal residues [4] and that 
conjugation of oligonucleotides to steroids promotes 
their binding to blood cells [5], thus changing the distri- 
bution and increasing their life time. In this report we 
describe experiments in which we have found that the 
oligonucleotides interact with certain blood proteins, 
namely, serum albumin and the immunoglobulins M 
and G. 
2. Materials and methods 
Oligodeoxynucleotides and the radiolabeled reactive derivatives of 
oligonucleotides were synthesized as described earlier [68]. The com- 
pounds were 90-95% pure as shown by electrophoresis the specific 
radioactivity being 50 Wmmol. Heparin and bovine serum albumin 
were from Sigma. Total fractions of the human immunoglobulins G 
and mouse immunoglobulin M were purchased from Biosan (Novosi- 
birsk). The human myoglobin-specific mouse antibodies 4D4 and 8D6 
were characterized elsewhere [9]. Human blood serum was prepared by 
standard procedures and stored at - 20” C. 
Affinity modification of the proteins was performed in physiological 
salt solution (0.14 M NaCl, 0.01 M NaH,PO,, pH 7.5) in the presence 
of various concentrations of the alkylating oligonucleotide derivatives. 
In the competition experiments, the reaction samples were supple- 
mented with competitors, which were introduced before the reactive 
compounds. Incubation was for 40 min at 37°C. The reaction was 
stopped by the addition of the equal volume of 0.06 M Tris-HCl, pH 
6.8, containing 2% SDS, 2% 2-mercaptoethanol and 20% glycerol fol- 
lowed by incubation for 5 min at 100°C. The labeled proteins were 
analyzed by SDS electrophoresis in gradient polyacrylamide gels (7- 
25%), according to Laemmli [lo]. the gels were autoradiographed and 
the films scanned to quantitate the data. 
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3. Results and discussion 
Affinity modification is an easy method to investigate 
macromolecular interactions of biologically active com- 
pounds. Oligonucleotides are large molecules allowing 
conjugation of reactive groups which does not interfere 
with their binding to the complementary nucleic acids 
and proteins [l]. In this study we have used a reactive 
alkylating aromatic 2chloroethylamino group, which 
can interact with both nucleic acids and proteins. The 
group was conjugated to the terminal phosphate which 
is the least important position for interactions of ol- 
igonucleotides. 
We incubated whole human blood serum with a 32P- 
labeled alkylating derivative of (PT),~, to label proteins 
capable of interacting with oligonucleotides. Results of 
the labeling experiments how (Fig. 1) that there are a 
few proteins in the serum which can interact with ol- 
igonucleotides. Among the labeled proteins we have 
found those corresponding to the immunoglobulins G 
and M according to their electrophoretic mobility. Ex- 
periments with the isolated pure immunoglobulins G and 
M have confirmed that the oligonucleotide derivatives 
react with these proteins under the conditions used 
(Fig. 2). The reactivity changed in the order: 
IgM > IgG > albumin. The oligonucleotide affinity to 
the proteins (dissociating constants) may be estimated 
[l l] as 4 and 6 ,uM for IgM and IgG, and about 20 ,uM 
for albumin. 
To investigate the specificity of interaction of the ol- 
igonucleotides with the proteins, we performed affinity 
modification of the proteins by an alkylating derivative 
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Fig. 1. Labeling of the human blood plasma proteins with the alkylating 
oligonucleotide derivative ClRCH,NH(pT),,. Autoradiogram of the 
SDS electrophoresis n the polyacrylamide gel. Proteins were incubated 
with 10 PM reactive derivative of oligonucleotide for 30 min at 37°C. 
Lanes l-3, IgG, IgM and bovine serum albumin, respectively. Lanes 
4-7, human serum incubated with 1.2, 2.5, 5.0 and 10 ,uM reagent. 
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Fig. 2. Effect of the reagent concentration on the specific labeling of 
the proteins. Albumin (*), IgG (0) and IgM (B) (all at 1 PM concentra- 
tion) were incubated with “P-labeled ClRCH,NH(pT),, in buffered 
(pH 7.5) physiological salt solution for 30 min at 37°C. pl6], ,uM - the 
alkylating reagent concentration in micromoles. Modification, specific 
“P label incorporation in the protein bands (arbitrary units). 
of oligothymidylate in the presence of various competi- 
tors: oligonucleotides, heparin and dsDNA. The com- 
pounds competed efficiently with the reagent in the 
reaction with immunoglobulins. Since some of these 
compounds were not nucleophilic in nature, we sug- 
gested that they inhibited the modification process by 
interfering with the binding of the reagents to the pro- 
teins. Because heparin showed high competitive effi- 
ciency, it was assumed that oligonucleotides bind to 
some polyanionic binding site of low specificity which is 
capable of tethering nucleic acids and polyanions. In the 
case of albumin, the competition was poor, suggesting 
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Fig. 3. Effect of competitors on the reaction of the blood serum proteins 
with alkylating derivative of oligothymidylate. Autoradiograph of the 
polyacrylamide gel. Lanes l-5, alkylation of bovine serum albumin; 
lanes 610, alkylation of IgM; lanes 1 l-15, alkylation of IgG. Reaction 
mixtures analyzed in lanes 1,6 and 11 contained 1 .O mg/ml dsDNA (0.5 
,uM). The reaction mixtures analyzed in lanes 2, 7 and 12 contained 50 
mg/ml heparin. The reaction mixtures analyzed in lanes 3, 8 and 13 
contained the 10 PM oligonucleotide pTGACCCTCTTCCCATT. The 
reaction mixtures analyzed in lanes 4,9 and 14 contained 10,~M (PT),~. 
Lanes 5, 10 and 15, the mixtures contained no competitors. 
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Fig. 4. Effect of the antigen (human myoglobin) on the reaction of the 
myoglobin-specific monoclonal mouse antibodies with the alkylating 
derivative CIRCH2NH(pT),6. Concentration of the derivative was 10 
PM. Lane 1, human myoglobin (4 PM); lanes 2 and 4, antibodies of the 
clones 4D4 and SD6 (1 PM); lanes 3 and 5, antibodies of the clones 4D4 
and SD6 (1 PM) in the presence of 4 PM human myoglobin. 
labeling without strong complex formation. Analysis of 
the labeled immunoglobulins has revealed that the ol- 
igonucleotide derivatives modified both heavy and light 
chains of the proteins. The competitors blocked the reac- 
tion with both the immunoglobulin chains (Fig. 3). 
Experiments with a myoglobin-specific mouse mono- 
clonal antibody (subtype Gl) have been performed to 
shed light on the localization of the oligonucleotide bind- 
ing sites. The antibodies 3D4 and 8D6 showed high affin- 
ities to myoglobin: Kd (dissociating constants) 6 nM and 
1 nM, respectively [9]. As shown in Fig. 4 the alkylating 
derivative of the oligonucleotide reacts with both mono- 
clonal antibodies. Introduction of the myoglobin (4 PM) 
in the reaction mixture inhibits the reaction completely 
suggesting the oligonucleotide binding at or in close 
proximity to the antigen binding site; the bound antigen 
shields the site from the oligonucleotides. An alternative 
E. Yu. Rykova et al. IFEBS Letters 344 (1994) 96-98 
explanation may be that the interaction with the specific 
antigen causes conformational change of the site which 
is responsible for the oligonucleotide binding. 
The described experiments how that oligonucleotides 
can interact with immunoglobulins. This interaction 
should be taken into account when considering the fate 
of oligonucleotides in the organism. Earlier we have 
found that the oligonucleotides bind with CD4 receptor 
[ 1 l] which is of the same protein family as immunoglob- 
ulins. The observed interactions pose the question if the 
interactions of nucleic acids with immunoglobulins and 
immunoglobulin-like receptors is of any biological sig- 
nificance. 
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